InsidersTradesSigma
Track the Terns Pharmaceuticals, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Health Care sector, Terns Pharmaceuticals, Inc. has recorded 58 insider filings. Market capitalisation: €1,040.1bn. The latest transaction was filed on 2 April 2026 (Cession). Among the most active insiders: Vignola Mark J.. The full history is accessible without an account.
58
Insider Decl.
n/a
Thresholds
€37m
30 ops.
Buy Volume
€7m
13 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Terns Pharmaceuticals, Inc. Strong Buy (bullish), based on 42 analysts. Average price target: US$1,507.38.
59Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 14,265 of 29,062 companies
52.5
score / 100
Value27
Quality79
FCF yld0.2%
Earn yld0.9%
EV/EBITDA51.0x
ROE67%
Gross mgn40%
Net mgn23%
Debt/EBITDA0.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 2 April 2026
Declarations58 total
942 shares@ US$52.752661.4% of flowCommon StockSEC:0001892413-26-000006:0
14,583 shares@ US$4.6424.3% of flowCommon StockSEC:0001872564-26-000008:0
14,583 shares@ US$4.6414.8% of flowCommon StockSEC:0001872564-26-000006:0
56,250 shares0Common StockSEC:0001892413-26-000004:0
150,000 shares0Common StockSEC:0001872564-26-000004:0
68,750 shares0Common StockSEC:0001563623-26-000002:0
21,551 shares@ US$4.6422.0% of flowCommon StockSEC:0001872564-26-000002:0
200 shares@ US$39.607.8% of flowCommon StockSEC:0001892413-26-000002:0
24,520 shares@ US$9.2460.1% of flowCommon StockSEC:0001799780-25-000004:0
944 shares@ US$7.84648.0% of flowCommon StockSEC:0001892413-25-000004:0
853 shares@ US$4.26714.2% of flowCommon StockSEC:0001562180-25-005308:0
5,000 shares@ US$3.926751.0% of flowCommon StockSEC:0001562180-25-005120:0
Canonical exit: 25 Sept 2025 (T+90)
23,314 shares@ US$3.870241.8% of flowCommon StockSEC:0001562180-25-005077:0
Canonical exit: 23 Sept 2025 (T+90)
5,000 shares@ US$3.75100.0% of flowCommon StockSEC:0001562180-25-004866:0
Canonical exit: 11 Sept 2025 (T+90)
952 shares@ US$2.48518.1% of flowCommon StockSEC:0001562180-25-002920:0
2,250 shares@ US$5.11100.0% of flowCommon StockSEC:0001562180-25-000853:0
Canonical exit: 28 Feb 2025 (T+90)
510 shares@ US$5.112.3% of flowCommon StockSEC:0001562180-25-000851:0
Canonical exit: 28 Feb 2025 (T+90)
8,129 shares@ US$5.723232.2% of flowCommon StockSEC:0001562180-25-000220:0
6,240 shares@ US$5.721526.4% of flowCommon StockSEC:0001562180-25-000219:0
4,481 shares@ US$5.714691.9% of flowCommon StockSEC:0001562180-25-000221:0
15,450 shares@ US$7.1597.7% of flowCommon StockSEC:0001562180-24-008254:0
Canonical exit: 5 Mar 2025 (T+90)
10,000 shares@ US$5.3634.9% of flowCommon StockSEC:0001562180-24-006794:0
17,235 shares@ US$1.8221.8% of flowCommon StockSEC:0001562180-24-006776:0
6,143 shares@ US$7.675133.5% of flowCommon StockSEC:0001562180-24-006019:0
25 of 58 declarations
关于 Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc.是一家生物制药公司，专注于开发代谢和肝脏疾病的创新疗法。该公司在纳斯达克上市，股票代码为TERN。